A phase II randomized, controlled, open-labeled (dose-blinded) dose finding study of the safety and efficacy of I-040202 in the treatment of patients with acute open tibial shaft fractures

Trial Profile

A phase II randomized, controlled, open-labeled (dose-blinded) dose finding study of the safety and efficacy of I-040202 in the treatment of patients with acute open tibial shaft fractures

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Feb 2017

At a glance

  • Drugs KUR-113 (Primary)
  • Indications Fracture
  • Focus Therapeutic Use
  • Sponsors Kuros Biosurgery
  • Most Recent Events

    • 20 Jan 2016 Primary endpoint 'Proportion of patients healed 6 months after the surgery' has been met, according to a Kuros Biosciences media release.
    • 10 Jul 2012 New source identified and integrated: ClinicalTrials.gov record NCT00533793.
    • 04 Jul 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top